PubMed:9398087 JSONTXT

{"project":"CL-cell","denotations":[{"id":"T1","span":{"begin":317,"end":329},"obj":"Cell"},{"id":"T2","span":{"begin":810,"end":823},"obj":"Cell"},{"id":"T3","span":{"begin":1254,"end":1267},"obj":"Cell"}],"attributes":[{"id":"A1","pred":"cl_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/CL:0000094"},{"id":"A2","pred":"cl_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/CL:0000836"},{"id":"A3","pred":"cl_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/CL:0000836"}],"text":"Differanisole A, a novel antitumor antibiotic, enhances growth inhibition and differentiation of human myeloid leukemia cells induced by 9-cis retinoic acid.\nDifferanisole A, 3,5-dichloro-2-hydroxy-4-methoxy-6-n-propylbenzoic acid, inhibited growth of human myeloid leukemia cells. The compound induced G1 arrest and granulocytic differentiation of HL-60 cells, although the differentiation-inducing effect was modest. Differanisole A and 9-cis retinoic acid (9cisRA) synergistically inhibited the growth and induced functional and morphologic differentiation of HL-60 and NB4 cells, whereas the combined treatment with differanisole A and all-trans retinoic acid or 1alpha,25-dihydroxyvitamin D3 was less effective. Similar results were obtained in primary culture of leukemia cells from a patient with acute promyelocytic leukemia. The synergistic effect on growth inhibition and induction of differentiation required simultaneous treatment with differanisole A and 9cisRA. Differanisole A and an RXR-specific ligand (Ro47-5944) cooperatively inhibited the cell growth, while the combined effect of differanisole A and an RAR-specific ligand Am80 was just additive. Differanisole A in combination with 9cisRA may have implications for therapy of acute promyelocytic leukemia patients."}

{"project":"jnlpba-st-training","denotations":[{"id":"T1","span":{"begin":97,"end":125},"obj":"cell_type"},{"id":"T2","span":{"begin":252,"end":280},"obj":"cell_type"},{"id":"T3","span":{"begin":349,"end":360},"obj":"cell_line"},{"id":"T4","span":{"begin":563,"end":582},"obj":"cell_line"},{"id":"T5","span":{"begin":769,"end":783},"obj":"cell_type"}],"text":"Differanisole A, a novel antitumor antibiotic, enhances growth inhibition and differentiation of human myeloid leukemia cells induced by 9-cis retinoic acid.\nDifferanisole A, 3,5-dichloro-2-hydroxy-4-methoxy-6-n-propylbenzoic acid, inhibited growth of human myeloid leukemia cells. The compound induced G1 arrest and granulocytic differentiation of HL-60 cells, although the differentiation-inducing effect was modest. Differanisole A and 9-cis retinoic acid (9cisRA) synergistically inhibited the growth and induced functional and morphologic differentiation of HL-60 and NB4 cells, whereas the combined treatment with differanisole A and all-trans retinoic acid or 1alpha,25-dihydroxyvitamin D3 was less effective. Similar results were obtained in primary culture of leukemia cells from a patient with acute promyelocytic leukemia. The synergistic effect on growth inhibition and induction of differentiation required simultaneous treatment with differanisole A and 9cisRA. Differanisole A and an RXR-specific ligand (Ro47-5944) cooperatively inhibited the cell growth, while the combined effect of differanisole A and an RAR-specific ligand Am80 was just additive. Differanisole A in combination with 9cisRA may have implications for therapy of acute promyelocytic leukemia patients."}

{"project":"pubmed-sentences-benchmark","denotations":[{"id":"S1","span":{"begin":0,"end":157},"obj":"Sentence"},{"id":"S2","span":{"begin":158,"end":281},"obj":"Sentence"},{"id":"S3","span":{"begin":282,"end":418},"obj":"Sentence"},{"id":"S4","span":{"begin":419,"end":716},"obj":"Sentence"},{"id":"S5","span":{"begin":717,"end":833},"obj":"Sentence"},{"id":"S6","span":{"begin":834,"end":975},"obj":"Sentence"},{"id":"S7","span":{"begin":976,"end":1167},"obj":"Sentence"},{"id":"S8","span":{"begin":1168,"end":1286},"obj":"Sentence"}],"text":"Differanisole A, a novel antitumor antibiotic, enhances growth inhibition and differentiation of human myeloid leukemia cells induced by 9-cis retinoic acid.\nDifferanisole A, 3,5-dichloro-2-hydroxy-4-methoxy-6-n-propylbenzoic acid, inhibited growth of human myeloid leukemia cells. The compound induced G1 arrest and granulocytic differentiation of HL-60 cells, although the differentiation-inducing effect was modest. Differanisole A and 9-cis retinoic acid (9cisRA) synergistically inhibited the growth and induced functional and morphologic differentiation of HL-60 and NB4 cells, whereas the combined treatment with differanisole A and all-trans retinoic acid or 1alpha,25-dihydroxyvitamin D3 was less effective. Similar results were obtained in primary culture of leukemia cells from a patient with acute promyelocytic leukemia. The synergistic effect on growth inhibition and induction of differentiation required simultaneous treatment with differanisole A and 9cisRA. Differanisole A and an RXR-specific ligand (Ro47-5944) cooperatively inhibited the cell growth, while the combined effect of differanisole A and an RAR-specific ligand Am80 was just additive. Differanisole A in combination with 9cisRA may have implications for therapy of acute promyelocytic leukemia patients."}

{"project":"genia-medco-coref","denotations":[{"id":"C1","span":{"begin":0,"end":15},"obj":"NP"},{"id":"C2","span":{"begin":17,"end":45},"obj":"NP"},{"id":"C3","span":{"begin":97,"end":125},"obj":"NP"},{"id":"C4","span":{"begin":137,"end":156},"obj":"NP"},{"id":"C5","span":{"begin":158,"end":173},"obj":"NP"},{"id":"C6","span":{"begin":175,"end":230},"obj":"NP"},{"id":"C7","span":{"begin":252,"end":280},"obj":"NP"},{"id":"C9","span":{"begin":419,"end":434},"obj":"NP"},{"id":"C10","span":{"begin":439,"end":467},"obj":"NP"},{"id":"C8","span":{"begin":419,"end":467},"obj":"NP"},{"id":"C11","span":{"begin":620,"end":635},"obj":"NP"},{"id":"C12","span":{"begin":789,"end":832},"obj":"NP"},{"id":"C14","span":{"begin":948,"end":963},"obj":"NP"},{"id":"C15","span":{"begin":968,"end":974},"obj":"NP"},{"id":"C13","span":{"begin":948,"end":974},"obj":"NP"},{"id":"C16","span":{"begin":976,"end":991},"obj":"NP"},{"id":"C17","span":{"begin":1101,"end":1116},"obj":"NP"},{"id":"C18","span":{"begin":1168,"end":1183},"obj":"NP"},{"id":"C19","span":{"begin":1204,"end":1210},"obj":"NP"},{"id":"C20","span":{"begin":1248,"end":1285},"obj":"NP"}],"relations":[{"id":"R1","pred":"coref-appos","subj":"C2","obj":"C1"},{"id":"R2","pred":"coref-ident","subj":"C5","obj":"C1"},{"id":"R3","pred":"coref-appos","subj":"C6","obj":"C5"},{"id":"R4","pred":"coref-ident","subj":"C7","obj":"C3"},{"id":"R5","pred":"coref-ident","subj":"C9","obj":"C5"},{"id":"R6","pred":"coref-ident","subj":"C10","obj":"C4"},{"id":"R7","pred":"coref-ident","subj":"C11","obj":"C9"},{"id":"R8","pred":"coref-ident","subj":"C14","obj":"C11"},{"id":"R9","pred":"coref-ident","subj":"C15","obj":"C10"},{"id":"R10","pred":"coref-ident","subj":"C13","obj":"C8"},{"id":"R11","pred":"coref-ident","subj":"C16","obj":"C14"},{"id":"R12","pred":"coref-ident","subj":"C17","obj":"C16"},{"id":"R13","pred":"coref-ident","subj":"C18","obj":"C17"},{"id":"R14","pred":"coref-ident","subj":"C19","obj":"C15"},{"id":"R15","pred":"coref-ident","subj":"C20","obj":"C12"}],"text":"Differanisole A, a novel antitumor antibiotic, enhances growth inhibition and differentiation of human myeloid leukemia cells induced by 9-cis retinoic acid.\nDifferanisole A, 3,5-dichloro-2-hydroxy-4-methoxy-6-n-propylbenzoic acid, inhibited growth of human myeloid leukemia cells. The compound induced G1 arrest and granulocytic differentiation of HL-60 cells, although the differentiation-inducing effect was modest. Differanisole A and 9-cis retinoic acid (9cisRA) synergistically inhibited the growth and induced functional and morphologic differentiation of HL-60 and NB4 cells, whereas the combined treatment with differanisole A and all-trans retinoic acid or 1alpha,25-dihydroxyvitamin D3 was less effective. Similar results were obtained in primary culture of leukemia cells from a patient with acute promyelocytic leukemia. The synergistic effect on growth inhibition and induction of differentiation required simultaneous treatment with differanisole A and 9cisRA. Differanisole A and an RXR-specific ligand (Ro47-5944) cooperatively inhibited the cell growth, while the combined effect of differanisole A and an RAR-specific ligand Am80 was just additive. Differanisole A in combination with 9cisRA may have implications for therapy of acute promyelocytic leukemia patients."}

{"project":"GENIAcorpus","denotations":[{"id":"T1","span":{"begin":0,"end":15},"obj":"other_organic_compound"},{"id":"T2","span":{"begin":25,"end":45},"obj":"other_organic_compound"},{"id":"T3","span":{"begin":97,"end":125},"obj":"cell_type"},{"id":"T4","span":{"begin":137,"end":156},"obj":"other_organic_compound"},{"id":"T5","span":{"begin":158,"end":173},"obj":"other_organic_compound"},{"id":"T6","span":{"begin":175,"end":230},"obj":"other_organic_compound"},{"id":"T7","span":{"begin":252,"end":280},"obj":"cell_type"},{"id":"T8","span":{"begin":303,"end":312},"obj":"other_name"},{"id":"T9","span":{"begin":317,"end":345},"obj":"other_name"},{"id":"T10","span":{"begin":349,"end":360},"obj":"cell_line"},{"id":"T11","span":{"begin":419,"end":434},"obj":"other_organic_compound"},{"id":"T12","span":{"begin":439,"end":458},"obj":"other_organic_compound"},{"id":"T13","span":{"begin":460,"end":466},"obj":"other_organic_compound"},{"id":"T14","span":{"begin":620,"end":635},"obj":"other_organic_compound"},{"id":"T15","span":{"begin":640,"end":663},"obj":"other_organic_compound"},{"id":"T16","span":{"begin":667,"end":696},"obj":"other_organic_compound"},{"id":"T17","span":{"begin":769,"end":783},"obj":"cell_type"},{"id":"T18","span":{"begin":804,"end":832},"obj":"other_name"},{"id":"T19","span":{"begin":948,"end":963},"obj":"other_organic_compound"},{"id":"T20","span":{"begin":968,"end":974},"obj":"other_organic_compound"},{"id":"T21","span":{"begin":976,"end":991},"obj":"other_organic_compound"},{"id":"T22","span":{"begin":999,"end":1018},"obj":"other_organic_compound"},{"id":"T23","span":{"begin":1020,"end":1029},"obj":"other_organic_compound"},{"id":"T24","span":{"begin":1101,"end":1116},"obj":"other_organic_compound"},{"id":"T25","span":{"begin":1124,"end":1143},"obj":"other_organic_compound"},{"id":"T26","span":{"begin":1144,"end":1148},"obj":"other_organic_compound"},{"id":"T27","span":{"begin":1168,"end":1183},"obj":"other_organic_compound"},{"id":"T28","span":{"begin":1204,"end":1210},"obj":"other_organic_compound"},{"id":"T29","span":{"begin":1248,"end":1276},"obj":"other_name"}],"text":"Differanisole A, a novel antitumor antibiotic, enhances growth inhibition and differentiation of human myeloid leukemia cells induced by 9-cis retinoic acid.\nDifferanisole A, 3,5-dichloro-2-hydroxy-4-methoxy-6-n-propylbenzoic acid, inhibited growth of human myeloid leukemia cells. The compound induced G1 arrest and granulocytic differentiation of HL-60 cells, although the differentiation-inducing effect was modest. Differanisole A and 9-cis retinoic acid (9cisRA) synergistically inhibited the growth and induced functional and morphologic differentiation of HL-60 and NB4 cells, whereas the combined treatment with differanisole A and all-trans retinoic acid or 1alpha,25-dihydroxyvitamin D3 was less effective. Similar results were obtained in primary culture of leukemia cells from a patient with acute promyelocytic leukemia. The synergistic effect on growth inhibition and induction of differentiation required simultaneous treatment with differanisole A and 9cisRA. Differanisole A and an RXR-specific ligand (Ro47-5944) cooperatively inhibited the cell growth, while the combined effect of differanisole A and an RAR-specific ligand Am80 was just additive. Differanisole A in combination with 9cisRA may have implications for therapy of acute promyelocytic leukemia patients."}

{"project":"HP-phenotype","denotations":[{"id":"T1","span":{"begin":103,"end":119},"obj":"Phenotype"},{"id":"T2","span":{"begin":258,"end":274},"obj":"Phenotype"},{"id":"T3","span":{"begin":769,"end":777},"obj":"Phenotype"},{"id":"T4","span":{"begin":804,"end":832},"obj":"Phenotype"},{"id":"T5","span":{"begin":1248,"end":1276},"obj":"Phenotype"}],"attributes":[{"id":"A1","pred":"hp_id","subj":"T1","obj":"HP:0012324"},{"id":"A2","pred":"hp_id","subj":"T2","obj":"HP:0012324"},{"id":"A3","pred":"hp_id","subj":"T3","obj":"HP:0001909"},{"id":"A4","pred":"hp_id","subj":"T4","obj":"HP:0004836"},{"id":"A5","pred":"hp_id","subj":"T5","obj":"HP:0004836"}],"namespaces":[{"prefix":"HP","uri":"http://purl.obolibrary.org/obo/HP_"}],"text":"Differanisole A, a novel antitumor antibiotic, enhances growth inhibition and differentiation of human myeloid leukemia cells induced by 9-cis retinoic acid.\nDifferanisole A, 3,5-dichloro-2-hydroxy-4-methoxy-6-n-propylbenzoic acid, inhibited growth of human myeloid leukemia cells. The compound induced G1 arrest and granulocytic differentiation of HL-60 cells, although the differentiation-inducing effect was modest. Differanisole A and 9-cis retinoic acid (9cisRA) synergistically inhibited the growth and induced functional and morphologic differentiation of HL-60 and NB4 cells, whereas the combined treatment with differanisole A and all-trans retinoic acid or 1alpha,25-dihydroxyvitamin D3 was less effective. Similar results were obtained in primary culture of leukemia cells from a patient with acute promyelocytic leukemia. The synergistic effect on growth inhibition and induction of differentiation required simultaneous treatment with differanisole A and 9cisRA. Differanisole A and an RXR-specific ligand (Ro47-5944) cooperatively inhibited the cell growth, while the combined effect of differanisole A and an RAR-specific ligand Am80 was just additive. Differanisole A in combination with 9cisRA may have implications for therapy of acute promyelocytic leukemia patients."}

{"project":"mondo_disease","denotations":[{"id":"T1","span":{"begin":103,"end":119},"obj":"Disease"},{"id":"T2","span":{"begin":258,"end":274},"obj":"Disease"},{"id":"T3","span":{"begin":769,"end":777},"obj":"Disease"},{"id":"T4","span":{"begin":804,"end":832},"obj":"Disease"},{"id":"T5","span":{"begin":1248,"end":1276},"obj":"Disease"}],"attributes":[{"id":"A1","pred":"mondo_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/MONDO_0004643"},{"id":"A2","pred":"mondo_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/MONDO_0004643"},{"id":"A3","pred":"mondo_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/MONDO_0005059"},{"id":"A4","pred":"mondo_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/MONDO_0012883"},{"id":"A5","pred":"mondo_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/MONDO_0012883"}],"text":"Differanisole A, a novel antitumor antibiotic, enhances growth inhibition and differentiation of human myeloid leukemia cells induced by 9-cis retinoic acid.\nDifferanisole A, 3,5-dichloro-2-hydroxy-4-methoxy-6-n-propylbenzoic acid, inhibited growth of human myeloid leukemia cells. The compound induced G1 arrest and granulocytic differentiation of HL-60 cells, although the differentiation-inducing effect was modest. Differanisole A and 9-cis retinoic acid (9cisRA) synergistically inhibited the growth and induced functional and morphologic differentiation of HL-60 and NB4 cells, whereas the combined treatment with differanisole A and all-trans retinoic acid or 1alpha,25-dihydroxyvitamin D3 was less effective. Similar results were obtained in primary culture of leukemia cells from a patient with acute promyelocytic leukemia. The synergistic effect on growth inhibition and induction of differentiation required simultaneous treatment with differanisole A and 9cisRA. Differanisole A and an RXR-specific ligand (Ro47-5944) cooperatively inhibited the cell growth, while the combined effect of differanisole A and an RAR-specific ligand Am80 was just additive. Differanisole A in combination with 9cisRA may have implications for therapy of acute promyelocytic leukemia patients."}

{"project":"NCBITAXON","denotations":[{"id":"T1","span":{"begin":97,"end":102},"obj":"OrganismTaxon"},{"id":"T2","span":{"begin":252,"end":257},"obj":"OrganismTaxon"},{"id":"T3","span":{"begin":791,"end":798},"obj":"OrganismTaxon"}],"attributes":[{"id":"A1","pred":"db_id","subj":"T1","obj":"9606"},{"id":"A2","pred":"db_id","subj":"T2","obj":"9606"},{"id":"A3","pred":"db_id","subj":"T3","obj":"9606"}],"text":"Differanisole A, a novel antitumor antibiotic, enhances growth inhibition and differentiation of human myeloid leukemia cells induced by 9-cis retinoic acid.\nDifferanisole A, 3,5-dichloro-2-hydroxy-4-methoxy-6-n-propylbenzoic acid, inhibited growth of human myeloid leukemia cells. The compound induced G1 arrest and granulocytic differentiation of HL-60 cells, although the differentiation-inducing effect was modest. Differanisole A and 9-cis retinoic acid (9cisRA) synergistically inhibited the growth and induced functional and morphologic differentiation of HL-60 and NB4 cells, whereas the combined treatment with differanisole A and all-trans retinoic acid or 1alpha,25-dihydroxyvitamin D3 was less effective. Similar results were obtained in primary culture of leukemia cells from a patient with acute promyelocytic leukemia. The synergistic effect on growth inhibition and induction of differentiation required simultaneous treatment with differanisole A and 9cisRA. Differanisole A and an RXR-specific ligand (Ro47-5944) cooperatively inhibited the cell growth, while the combined effect of differanisole A and an RAR-specific ligand Am80 was just additive. Differanisole A in combination with 9cisRA may have implications for therapy of acute promyelocytic leukemia patients."}

{"project":"Anatomy-UBERON","denotations":[{"id":"T1","span":{"begin":317,"end":329},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"uberon_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/CL_0000094"}],"text":"Differanisole A, a novel antitumor antibiotic, enhances growth inhibition and differentiation of human myeloid leukemia cells induced by 9-cis retinoic acid.\nDifferanisole A, 3,5-dichloro-2-hydroxy-4-methoxy-6-n-propylbenzoic acid, inhibited growth of human myeloid leukemia cells. The compound induced G1 arrest and granulocytic differentiation of HL-60 cells, although the differentiation-inducing effect was modest. Differanisole A and 9-cis retinoic acid (9cisRA) synergistically inhibited the growth and induced functional and morphologic differentiation of HL-60 and NB4 cells, whereas the combined treatment with differanisole A and all-trans retinoic acid or 1alpha,25-dihydroxyvitamin D3 was less effective. Similar results were obtained in primary culture of leukemia cells from a patient with acute promyelocytic leukemia. The synergistic effect on growth inhibition and induction of differentiation required simultaneous treatment with differanisole A and 9cisRA. Differanisole A and an RXR-specific ligand (Ro47-5944) cooperatively inhibited the cell growth, while the combined effect of differanisole A and an RAR-specific ligand Am80 was just additive. Differanisole A in combination with 9cisRA may have implications for therapy of acute promyelocytic leukemia patients."}